iTeos Therapeutics, Inc. (ITOS)
NASDAQ$7.32
Market Cap
$279.58M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
343 of 924
Rank in Industry
200 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ITOS Insider Trading Activity
ITOS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $38,635 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Gall Matthew | Chief Financial Officer | 1 | $38,635 | 0 | $0 | $38,635 |
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote …
Insider Activity of iTeos Therapeutics, Inc.
Over the last 12 months, insiders at iTeos Therapeutics, Inc. have bought $38,635 and sold $0 worth of iTeos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at iTeos Therapeutics, Inc. have bought $31.5M and sold $63.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gall Matthew (Chief Financial Officer) — $38,635.
The last purchase of 5,000 shares for transaction amount of $38,635 was made by Gall Matthew (Chief Financial Officer) on 2024‑11‑19.
List of Insider Buy and Sell Transactions, iTeos Therapeutics, Inc.
| 2024-11-19 | Gall Matthew | Chief Financial Officer | 5,000 0.0135% | $7.73 | $38,635 | -3.92% | ||
| 2023-10-12 | Gall Matthew | Chief Financial Officer | 5,000 0.0136% | $8.37 | $41,850 | +30.92% | ||
| 2023-08-23 | Sale | Boxer Capital, LLC | 350,000 1.1785% | $16.26 | $5.69M | -16.00% | ||
| 2022-06-08 | Sale | Hallal David | 1,171 0.0033% | $19.51 | $22,846 | -3.14% | ||
| 2022-05-09 | Sale | Davis Aaron I. | 337,109 0.7412% | $18.25 | $6.15M | -17.43% | ||
| 2022-04-28 | Sale | Davis Aaron I. | 115,000 0.3152% | $27.01 | $3.11M | -29.86% | ||
| 2022-04-18 | Sale | Detheux Michel | Chief Executive Officer | 11,467 0.0326% | $31.87 | $365,453 | -37.63% | |
| 2022-03-22 | Davis Aaron I. | 20,000 0.0553% | $32.85 | $656,980 | -39.63% | |||
| 2022-03-21 | Sale | Detheux Michel | Chief Executive Officer | 5,822 0.0167% | $33.44 | $194,688 | -38.51% | |
| 2022-03-17 | Sale | LEWIS JOSEPH | 575,201 1.5917% | $35.25 | $20.28M | -43.47% | ||
| 2022-03-11 | Sale | Lager Joanne Jenkins | Chief Medical Officer | 3,500 0.0099% | $36.01 | $126,035 | -43.21% | |
| 2022-03-01 | Sale | McGrath Yvonne | Chief Scientific Officer | 10,000 0.0283% | $36.76 | $367,570 | -43.58% | |
| 2022-02-23 | Sale | Detheux Michel | Chief Executive Officer | 14,500 0.0414% | $34.34 | $497,905 | -38.35% | |
| 2022-02-11 | Sale | Lager Joanne Jenkins | Chief Medical Officer | 3,500 0.0101% | $35.85 | $125,459 | -40.32% | |
| 2022-01-25 | Sale | Detheux Michel | Chief Executive Officer | 14,500 0.0403% | $35.68 | $517,378 | -40.58% | |
| 2022-01-14 | Sale | Lager Joanne Jenkins | Chief Medical Officer | 3,500 0.0098% | $39.32 | $137,614 | -45.75% | |
| 2022-01-05 | Sale | GADICKE ANSBERT | 10 percent owner | 30,347 0.0856% | $42.03 | $1.28M | -46.62% | |
| 2022-01-05 | Sale | MPM BIOVENTURES 2018, L.P. | 10 percent owner | 18,135 0.0512% | $42.03 | $762,214 | -46.62% | |
| 2022-01-05 | Sale | MPM BioVentures 2014, L.P. | 10 percent owner | 18,135 0.0512% | $42.03 | $762,214 | -46.62% | |
| 2022-01-04 | Sale | GADICKE ANSBERT | 10 percent owner | 215,122 0.6156% | $42.66 | $9.18M | -46.05% |
Total: 186
*Gray background shows transactions not older than one year
Insider Historical Profitability
28.67%
| Gall Matthew | Chief Financial Officer | 65429 0.1713% | $478,940.28 | 3 | 1 | +20.36% |
| GADICKE ANSBERT | 10 percent owner | 4484728 11.7419% | $32.83M | 1 | 43 | +45.66% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 4417259 11.5652% | $32.33M | 1 | 0 | +45.66% |
| MPM BioVentures 2014, L.P. | 10 percent owner | 2738785 7.1707% | $20.05M | 1 | 43 | +45.66% |
| Davis Aaron I. | 2154058 5.6397% | $15.77M | 2 | 2 | +3.01% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$99,438,720 | 81 | 6.74% | $290.44M | |
$5,911,307 | 70 | -1.38% | $309.77M | |
$11,468,215 | 44 | 17.78% | $246.73M | |
$17,983,739 | 41 | 102.87% | $266.1M | |
$56,550,550 | 22 | 50.17% | $270.11M |
ITOS Institutional Investors: Active Positions
| Increased Positions | 78 | +43.09% | 11M | +29.85% |
| Decreased Positions | 83 | -45.86% | 10M | -28.1% |
| New Positions | 27 | New | 5M | New |
| Sold Out Positions | 39 | Sold Out | 4M | Sold Out |
| Total Postitions | 176 | -2.76% | 37M | +1.75% |
ITOS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $27,599.00 | 10.27% | 3.8M | -81,040 | -2.09% | 2024-12-31 |
| Boxer Capital, Llc | $21,395.00 | 7.97% | 2.95M | 0 | 0% | 2024-09-30 |
| Mpm Asset Management Llc | $19,884.00 | 7.4% | 2.74M | 0 | 0% | 2024-12-31 |
| Bvf Inc/Il | $16,880.00 | 6.28% | 2.33M | +2M | New | 2024-12-31 |
| Ra Capital Management, L.P. | $15,190.00 | 5.66% | 2.09M | -1M | -34.3% | 2024-12-31 |
| Jpmorgan Chase & Co | $15,019.00 | 5.59% | 2.07M | +2M | +342.69% | 2024-12-31 |
| Mpm Bioimpact Llc | $12,676.00 | 4.72% | 1.75M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $11,863.00 | 4.42% | 1.63M | -22,781 | -1.38% | 2024-12-31 |
| Citadel Advisors Llc | $10,398.00 | 3.87% | 1.43M | +196,003 | +15.86% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $8,785.00 | 3.27% | 1.21M | +163,880 | +15.66% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.